First volunteers ready to take part in COVID-19 human trials
The First Australians to take part in human clinical trials of a possible coronavirus vaccine will be dosed up with an experimental drug next week.
More than 100 volunteers in Brisbane and Melbourne are taking part in the trials for a vaccine being developed by the US biopharma Novavax.
Australian firm Q-Pharm is conducting the trial of the Novavax candidate, NVX-CoV2373, as well as phase 1 trials of a vaccine being developed by Queensland University researchers, The Australian reports.
Q-Pharm's principal investigator Paul Griffin said many vaccine candidates looked promising.
"It's really remarkable that we've been able to progress so quickly," Professor Griffin said.
"I think they're both really good candidates. If they weren't really promising they wouldn't even be contemplating trialling them in humans."
NVX-CoV2373 was created using nanoparticle technology to generate antigen derived from the distinctive coronavirus spike protein.
The vaccine aims to enhance the immune response and stimulate high levels of neutralising antibodies which are found naturally in people who have recovered from COVID-19.
Q-Pharm, which is part of the Nucleus Network phase 1 clinical research organisation, will now begin to choose healthy people from a pool of volunteers.
The development comes after another US firm, Moderna, announced positive results from initial clinical trials of its experimental vaccine, which it hopes to have to market by January.
It is moving to large-scale human trials in July.
Australian researchers are recruiting 2000 healthcare workers to test whether hydroxychloroquine works to stave off the virus.
Fourteen hospitals across Australia are taking part in the hydroxychloroquine trial being run by the Walter and Eliza Hall Institute of Medical Research, The Australian reports.
Head of the trial Marc Pelligrini said test tube studies showed hydroxychloroquine can restrict the replication of the virus, raising hopes it could be used as a preventive treatment.
"Our number of cases is low in Australia, and this really gives us the perfect opportunity to dedicate our resources to being prepared for potentially a next wave," Professor Pelligrini said. "We need to be clear that this virus is not going to go away, it will be a threat for a very, very long time. And we really need to be prepared and discover new drugs that might be able to prevent people getting infected and getting sick."
Human trials of the UQ vaccine candidate are now just weeks away. A Dutch company is currently conducting preclinical studies of the UQ vaccine.
DON'T FORGET OTHER VACCINATIONS, PARENTS TOLD
Meanwhile, a US study has warned parents to make sure their children's vaccinations for other illnesses such as the mumps and measles are up to date as people come out of lockdown.
During the pandemic, the rates of childhood vaccinations have dropped significantly in the US as many parents have been reluctant to schedule well-child visits at their doctors' offices, for fear of contracting the coronavirus.
As a result, children have fallen behind on vaccinations for diseases like measles and pertussis, better known as whooping cough.
According to a new study released by the Centers for Disease Control and Prevention, the vaccination rates in May for children under 2 years old in Michigan fell to alarming rates, including fewer than half of infants 5 months or younger.
Researchers warned falling vaccination rates could jeopardise the herd immunity that communities have built up against a disease like measles. Public health officials estimate that a community vaccination rate from 93 per cent to 95 per cent is necessary to prevent a widespread outbreak of measles.
TRUMP AWARDS $A1.2BN DRUG CONTRACT
President Donald Trump's administration awarded a contract worth up to $812 million for a new US company to manufacture drugs and drug ingredients to fight COVID-19 on American soil, aiming to end dependence on other countries.
The administration has been looking to build up the ability to produce drugs and their raw materials in the United States after the global pandemic exposed the industry's dependence on China and India for its supply chain.
"For far too long, we've relied on foreign manufacturing and supply chains for our most important medicines and active pharmaceutical ingredients while placing America's health, safety, and national security at grave risk," Peter Navarro, director of the White House Office of Trade and Manufacturing Policy, said.
The US Department of Health and Human Services (HHS) said it had awarded a 4-year, $A540 million contract to privately-held Phlow Corp to make COVID-19 drugs, other essential drugs and their ingredients.
It comes as New York Governor Andrew Cuomo says any vaccine to prevent the coronavirus should be distributed fairly without regard for wealth, and called for US crisis leadership based on competence and not Twitter posts.
"You have to know what you are doing now - not just look like what you are doing, not just sound like what you are doing," Mr Cuomo said without naming US President Donald Trump, a Republican who frequently attacks his critics on Twitter.
"You have to be smart. You are not going to tweet your way through this," added Mr Cuomo, a Democrat.
There was no immediate response from Mr Trump.
Mr Cuomo spoke following news on Monday that an experimental COVID-19 vaccine made by biotech company Moderna produced protective antibodies in a small group of healthy volunteers.
"The vaccine must be available to all people," Mr Cuomo told a daily briefing on Tuesday.
"It can't be a situation where only the rich, only the privileged can get the vaccine because one company owns the rights and they can't produce enough for everyone." His comments came after the US mission in Geneva objected to parts of a World Health Organisation resolution on the pandemic.